View more job listings or post a job
Gilead Sciences Senior Research Associate, Drug Metabolism
Gilead Sciences Research Scientist, Drug Metabolism
Gilead Sciences Principal Scientist, Drug Metabolism
Gilead Sciences Research Scientist, Drug Metabolism
Theravance Biopharma Associate Scientist
Gilead Sciences Associate Scientist (Contractor)
Evotec/Genentech Contractor Scientific Researcher/Sr. Scientific Researcher in Protein Chemistry
Evotec/Genentech Contractor Scientific Researcher/Sr. Scientific Researcher in Protein Chemistry
Applied Photophysics Application Scientist
Genentech Associate Scientist(Contract)
Post a job


Promising Therapeutic Approaches and Translational Medicine to Advance Novel Therapeutics (A Joint Symposium by PBSS and Stanford SPARK Program)

Organizers: Kevin Grimes (Stanford), Shichang Miao (ChemoCentryx), Snow Ge (Nektar), Greg Wagner
Date: 3/7/2019
Time: 8:45-17:00
Registration fee (USD): Regular: $195; Academic: $50; Students/Postdocs & Unemployed: $20;
Location: Crowne Plaza, Foster City, CA
Major Sponsor:
Vendor show vendors registered to date: (6)Applied StemCell; Medpace; Novogene Corporation; Pacific BioLabs; PeproTech Inc; R&D Systems
Registration deadline:3/7/2019  (it will close sooner if the seating cap is reached)

About the Topic

This joint symposium between PBSS and the Stanford SPARK translational research program will review how industry and academia can work together to successfully translate academic research into commercial opportunities and will present examples of current and past SPARK projects. 

Academics often make promising discoveries that could lead to novel therapeutics, but lack the expertise to advance their science to a stage here commercial partners would be interested. The Stanford SPARK program is a collaboration between academic scientists and individuals from the local biopharmaceutical community who are willing to share their knowledge and expertise. SPARK is now in its twelfth year and nearly 50% of projects completing the program have been transferred to commercial partners. An additional 10% have entered investigator-initiated clinical trials. 


8:45- 8:55           Welcome Remarks (Shichang Miao, Kevin Grimes)

8:55- 9:30           Introduction to the Stanford SPARK Translational Research Program and Overview of Drug Discovery in the Academic Setting (Kevin Grimes, Professor, Co-Director of SPARK, Stanford)

9:30- 10:05         Peptide therapeutics for heart failure (or for Huntington's disease) (Daria Mochly-Rosen, Professor, Co-Director of SPARK, Stanford)

10:05-10:40        myc animal models and two therapeutic projects (Dean Felsher, Professor, Stanford)

10:40- 11:00       Break

11:00- 11:35       New treatment for dementia (Mehrdad Shamloo, Professor, Stanford)

11:35- 12:10       Antivirals targeting the host  (Shirit Einav, Professor, Stanford)

12:10- 1:00         Lunch

1:00- 1:35           Genomically-modfied cell therapies for IPEX syndrome (Rosa Bacchetta, Professor, Stanford)

1:35- 2:10           Drug target overview and selection: from the industry perspective (Nancy Pryer, Chief Development Officer, Nurix)

2:10- 2:45           Clinical candidate selection (John Link, VP  Medchem, Gilead)

2:45- 3:00           Break

3:00- 3:35           Funding for startups: seed/angel/VC funding and non-dilutive funding such as SBIR (Keith Wycoff, VP Research, Planet Biotechnology)

3:35- 4:10           GMP overview for small and/or large molecules (Kenneth Matthews, Gilead)

4:10- 4:45           IP considerations when starting a company: Avoid the Pitfalls and Set for Success (Janet Xiao, Partner, Morrison Foerster)

4:45- 5:15           Panel Discussion

2019-03-11, Clinical Trials Essentials: An Intensive One-Week Course (register for the full week or half day sessions)
2019-04-25, Tox 21 and New Approach Methodology (NAMs): Using Emerging Technologies to Improve Translational Research and Safety Assessment Predictions (jointly by SOT-NorCal & PBSS)
2019-05-06, CMC Development for Biologics: Purification, Formulation, Analytical Characterization, Production Systems, Regulatory and Product Development
2019-06-11, Advances in Immuno-Oncology (A Joint Symposium by PBSS and BioScience Forum)
2019-09-13, Biotransformation and Disposition of Larger Molecules: Peptides, Nucleotides, Proteins, mAbs, and ADCs
2019-10-03, Bioanalytical Method Validation & Regulated Bioanalysis: Fundamentals, the New FDA Guidance and Regulatory Trends
┬ęPharmaceutical & BioScience Society, International; Last Modified: 2/23/2019; Visited: 462; Admin Logon
Ads (in random order)
Submit a Text Ad
($200 for 2 months)

MicroConstants MicroConstants is a GLP-compliant Contract Research Organization focused on performing regulated bioanalysis, drug metabolism and PK analysis.
Submit a Text Ad